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Improper Trafficking of Melanocyte-Specific Proteins
in Hermansky–Pudlak Syndrome Type-5
Amanda Helip-Wooley1, Wendy Westbroek1, Heidi M. Dorward1, Amy Koshoffer2, Marjan Huizing1,
Raymond E. Boissy2 and William A. Gahl1
Hermansky–Pudlak syndrome (HPS) is a disorder of lysosome-related organelle biogenesis resulting in
melanosome dysfunction and absent platelet dense bodies. HPS patients have oculocutaneous albinism,
bruising, and bleeding. HPS-5 results from deficiency of the HPS5 protein, a component of the biogenesis of
lysosome-related organelles complex-2 (BLOC-2). HPS5 has an unknown function and lacks homology to known
proteins. We performed ultrastructural studies of HPS-5 melanocytes revealing predominantly early-stage
melanosomes with many small 3,4(OH)2-phenylalanine-positive vesicles throughout the cell body and
dendrites. These findings resemble the distinct ultrastructural features of HPS-3 melanocytes; HPS3 is also a
BLOC-2 component. Immunofluorescence and immunoEM studies showed decreased TYRP1 labeling in the
dendrites of HPS-5 melanocytes, and the overall abundance of TYRP1 was reduced. No substantial differences
were observed in the distribution or abundance of Pmel17 in HPS-5 melanocytes. In normal melanocytes,
endogenous tyrosinase colocalized with Pmel17 and TYRP1 in the perinuclear area and dendritic tips; this was
much reduced in HPS-5 melanocytes, particularly in the tips. We conclude that early stage melanosome
formation and Pmel17 trafficking are preserved in HPS5-deficient cells. Tyrosinase and TYRP1 are mistrafficked,
however, and fail to be efficiently delivered to melanosomes of HPS-5 melanocytes.
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INTRODUCTION
Hermansky–Pudlak syndrome (HPS [MIM: 203300]) is a
disorder of lysosome-related organelle biogenesis character-
ized by oculocutaneous albinism and a bleeding diathesis
(Hermansky and Pudlak, 1959; King et al., 2001; Huizing
et al., 2002; Bonifacino, 2004; Di Pietro and Dell’Angelica,
2005; Wei, 2006). Defects in the melanosome, a lysosome-
related organelle, cause HPS patients to manifest congenital
nystagmus, reduced visual acuity, and hypopigmentation of
the irides, skin, and hair (Simon et al., 1982; Witkop et al.,
1987; Summers et al., 1988). Complete absence of the
platelet dense body, another lysosome-related organelle,
results in impaired platelet aggregation with easy bruising,
epistaxis, and excessive bleeding following dental or surgical
procedures (Witkop et al., 1987; Gahl et al., 1998; King et al.,
2001).
Eight subtypes of HPS have been identified in humans
(HPS-1 through HPS-8); all exhibit oculocutaneous albinism
and absent platelet dense bodies. HPS-2 ([MIM: 603401])
results from mutations in the b3A subunit of adaptor
complex-3. The functions of the remaining HPS proteins
remain unknown, although several interact with each other in
the biogenesis of lysosome-related organelles complexes or
BLOCs (Li et al., 2003; Martina et al., 2003; Nazarian et al.,
2003; Zhang et al., 2003). Specifically, HPS1 and HPS4 form
BLOC-3 (Chiang et al., 2003; Martina et al., 2003; Nazarian
et al., 2003); the associated diseases HPS-1 ([MIM: 604982])
and HPS-4 ([MIM: 606682]) are relatively severe, with adult-
onset pulmonary fibrosis. HPS3, HPS5, and HPS6 comprise
BLOC-2 (Zhang et al., 2003; Di Pietro et al., 2004; Gautam
et al., 2004); patients with HPS-3 ([MIM: 606118]), HPS-5
([MIM: 607521]), or HPS-6 ([MIM: 607522]) have mild
hypopigmentation but no lung disease has been reported.
HPS7 ([MIM: 607145]) and HPS8 ([MIM: 609762]) are
components of BLOC-1; clinical descriptions are limited to
one brief case report each (Li et al., 2003; Morgan et al.,
2006). BLOC-specific clinical findings in murine models and
in human patients suggest a distinct role for each BLOC.
Individuals with HPS-3 disease have been extensively
described (Anikster et al., 2001; Huizing et al., 2001), and
their cultured fibroblasts and melanocytes have been
characterized (Boissy et al., 2005). However, HPS-5 patients
are very rare, and only limited studies of their fibroblasts are
available (Huizing et al., 2004). Herein we describe the
phenotype of human HPS-5 melanocytes using immunoblot-
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RESULTS
Biochemical characterization of HPS-5 melanocytes
Melanocytes were cultured from lightly pigmented normal
individuals and an HPS-5 patient (HPS106-5). Whole-cell
lysates containing 50 mg total protein were electrophoresed
and immunoblotted using HPS5 antibodies. Two closely
migrating bands were observed in normal melanocytes; these
bands were absent from HPS-5 melanocytes (Figure 1a). The
two bands migrated at approximately 120 and 130 kDa, close
to the predicted molecular weights of the long isoform a
(127 kDa) and the short isoform b (114 kDa) of HPS5 (GI
numbers 31657123 and 31657127).
Western blots indicated that the amount of TYRP1 protein
was drastically reduced in HPS-5 compared with normal
melanocytes, while tyrosinase protein was negligibly de-
creased (Figure 1b and c).
Tyrosinase was further assessed by measuring its enzy-
matic activity in intact and lysed melanocytes. Intact HPS-5
melanocytes demonstrated markedly reduced in vivo tyrosi-
nase activity compared with that of normal melanocytes from
either dark or light-skinned individuals (Figure 1d;
Po4 10–8 and Po110–10, respectively). In contrast, the
in vitro tyrosinase activity of lysed HPS-5 melanocytes
exceeded that of normals with light or medium pigmentation
(Figure 1e; Po0.0004 and Po0.003, respectively). Thus,
HPS-5 melanocytes contain a normal or greater than normal
amount of endogenous tyrosinase, with reduced or sup-
pressed function in vivo.
Ultrastructure of HPS-5 melanocytes
Cultured HPS-5 melanocytes exhibited predominantly lightly
pigmented early-stage (stage II–III) melanosomes (Figure 2a
and b, arrows). In contrast, normal melanocytes demon-
strated primarily darkly pigmented late-stage (stage IV)
melanosomes (Figure 2c and d). DOPA histochemistry
(indicating sites of tyrosinase activity) in both HPS-5 (Figure
3a and b) and normal (Figure 3c) melanocytes revealed
reaction product in the trans-Golgi network (TGN; G) and in
small (50–100 nm) vesicles (arrowheads in C) associated with
the TGN. In HPS-5 melanocytes, these small DOPA-positive
vesicles are not restricted to the TGN, as they are in normal
melanocytes, but instead are found throughout the cell body
and dendrites (Figure 3a and b, arrows). Additionally, HPS-5
melanocytes have a small number of melanosomes, notably
in the dendrites, that are devoid of DOPA reaction product
(Figure 3a, arrowheads).
Two different antibodies against TYRP1, the monoclonal
antibody MEL5 and the polyclonal aPEP1, were used to
localize the melanosomal protein TYRP1 in normal and HPS-
5 melanocytes using immunoelectron microscopy. EM
images of melanocytes labeled with aPEP1 are shown
(Figures 4 and 5; MEL5 labeling yielded similar results (not
shown)). More overall TYRP1 staining was observed in
normal melanocytes (Figure 4a) compared with HPS-5N
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Figure 1. Cultured melanocytes deficient in HPS5 demonstrate reduced in
vivo tyrosinase activity. Western blotting and assays of enzyme activity were
performed on melanocytes cultured from an HPS-5 patient and from
individuals with light (NHM L), medium (NHM M), or dark (NHM D)
pigmentation, as indicated. (a) Normal melanocyte lysates immunoblotted
with HPS5 antibodies demonstrate two bands corresponding to the long and
short isoforms of HPS5; these bands are absent from the HPS-5 melanocyte
lysate. a-Tubulin served as a loading control. (b) Normal and HPS-5
melanocyte lysates (25 mg total protein) immunoblotted and probed with
antibodies against TYRP1. TYRP1 protein abundance is markedly reduced in
HPS-5 melanocytes relative to normal. a-Tubulin served as a loading control.
(c) Normal and HPS-5 melanocyte lysates (25 mg total protein) immunoblotted
and probed with antibodies against tyrosinase. Tyrosinase protein is
minimally decreased in HPS-5 melanocytes relative to normal. a-Tubulin
served as a loading control. (d) In vivo tyrosine hydroxylase activity of intact
HPS-5 and control melanocytes. (e) In vitro tyrosine hydroxylase activity of
lysed HPS-5 and control melanocytes. Activity is expressed relative to the
NHM L control. Results are means7SD of three determinations.
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Figure 2. HPS-5 melanocytes contain more early melanosomes as
demonstrated by electron microscopy. (a, b) HPS-5 melanocytes viewed with
(a) low and (b) high magnification demonstrate predominantly lightly
pigmented early-stage (stages II–III) melanosomes (arrows) prominent
throughout the cell body. (c, d) Normal melanocytes (NHM) viewed with (c)
low and (d) high magnification contain primarily darkly pigmented late stage
(stage IV) melanosomes. Bar: (a, c) 3 mM and (b, d) 1 mM. N¼nucleus.
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melanocytes (Figure 5a). Immunogold label was quantified
on endosomal compartments and organelles, identified using
morphological criteria (see Figure S1). The majority of TYRP1
in normal melanocytes (36% of total aPEP1 and 30% of total
MEL5 labeling) was found in melanosomes with visible
fibrillar structures (Figure 4c, arrows; Table 1). In addition,
12% of total MEL5 and 13% of total aPEP1 labeling was on
early endosomes, and 26% of total MEL5 and 11% of total
aPEP1 labeling was on late endosomes, lysosomes, and
multivesicular bodies (Figure 4b; Table 1). HPS-5 melano-
cytes, in contrast, contained very little TYRP1 associated with
melanosomes (3% of total MEL5 and 8% of total aPEP1
labeling; Figure 5; Table 1). The majority of TYRP1 label in
HPS-5 melanocytes (68% of MEL5 and 44% of aPEP1) was on
small vesicles, outside of the Golgi region (Figure 5b–d,
arrows; Table 1). The same relative distribution of TYRP1
labeling was observed when all the TYRP1 particles in one
normal cell were counted and then compared to an equal
number of particles counted in multiple HPS-5 cells (data not
shown).
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Figure 3. HPS-5 melanocytes contain more DOPA-positive small vesicles
throughout the cells. Demonstrated by electron microscopy DOPA
histochemistry. (a) DOPA histochemistry in HPS-5 melanocytes reveals
reaction product in the TGN (G) and in small (50–100 nm) vesicles (arrows)
associated with the TGN and throughout the cell body and dendrites. A small
number of melanosomes in HPS-5 melanocytes, notably in the dendrites, are
devoid of DOPA reaction product (arrowheads). (b) DOPA histochemistry in
the perinuclear region of an HPS-5 melanocyte. Reaction product is detected
in small vesicles outside of the TGN (G) region (arrows). (c) DOPA
histochemistry reveals reaction product in small vesicles in the TGN (G)
region (arrowheads) of a normal human melanocyte, but not outside of this
region. Bar: (a–c) 1.5 mm; (a) insets, 1 mm. N¼ nucleus.
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Figure 4. TYRP1 localizes to melanosomes and endosomal structures in
normal melanocytes. Ultrathin cryosections of cultured normal melanocytes
with immunogold labeling for TYRP1 using the rabbit polyclonal antibody
aPEP1 (10 nm gold). (a) Normal melanocytes demonstrate abundant TYRP1
labeling on early endosomal structures (EE, arrows), small vesicles (asterisk),
and melanosomes (M, arrowheads). (b) TYRP1 labeling localized to electron
lucent early endosomal structures (EE, arrows) and early endosomes with
some electron-dense content (EE, arrowheads). (c) TYRP1 labeling (arrows)
localized to melanosomes (M) in a melanosome-rich peripheral area of the
cell. The majority of melanosomes that have gold label are stage III,
characterized by electron-dense melanin accumulation on the still visible
fibrils. Bar¼530 nm. Mit¼Mitochondrion.
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Figure 5. TYRP1 localizes to small vesicles in HPS-5 melanocytes. Ultrathin
cryosections of cultured HPS-5 melanocytes with immunogold labeling for
TYRP1 using the rabbit polyclonal antibody aPEP1 (10 nm gold). (a) HPS-5
melanocytes demonstrate minimal immunogold labeling for TYRP1 in a
melanosome-rich dendritic area. Label is found on an electron-lucent early
endosome (EE, arrowhead) and a small vesicle (arrow). (b) TYRP1 labeling in
the perinuclear area of an HPS-5 melanocyte is mainly localized to small
vesicles (arrows) that are not closely associated with the Golgi stacks (G).
Some TYRP1 label is also found on Golgi stacks. (c) TYRP1 label close to but
distinct from larger endosomes (arrows). (d) TYRP1 labeling on small vesicles
in the cell periphery (arrows). Bar¼530 nm. Mit¼Mitochondrion;
N¼Nucleus.
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Relative abundance of TYRP1
One striking finding in both the western analysis and
immunoEM studies was the marked reduction of TYRP1
staining in HPS-5 melanocytes relative to control. Confocal
images taken at low magnification (under identical staining
and imaging conditions) also demonstrated the reduced
intensity of TYRP1 (MEL5) staining (Figure 6a and d) in
untreated HPS-5 cells, supporting immunoblotting and
immunoEM findings (Figures 1b and 5a). The reduced
staining suggests that there is increased degradation of TYRP1
in HPS-5 melanocytes. To determine the site of TYRP1
degradation, inhibitors of lysosomal function (i.e., the
protonophore monensin) and proteasomal function (i.e.,
MG132) were used. Incubation of HPS-5 melanocytes with
5 mM monensin for 3 hours greatly increased MEL5 staining
(Figure 6e), but incubation with 0.5 mM MG132 for 3 hours
did not (Figure 6f). Normal melanocytes showed a slight
increase in MEL5 staining upon treatment with monensin or
MG132 (Figure 6b and c).
Distribution of melanosomal proteins
Immunofluorescence confocal microscopy was used to assess
the relative distribution of endogenous melanosomal proteins
in normal and HPS-5 melanocytes. Normal melanocytes
stained with MEL5 antibodies (recognizing TYRP1) exhibited
a vesicular pattern throughout the cell with a concentration of
MEL5-positive vesicles along the dendrites and in the tips
(Figure 7a, right panel). HPS-5 melanocytes lacked this
concentration of MEL5-positive vesicles in the dendrites and
tips; the majority of MEL5 staining was in the perinuclear area
(Figure 7b, right panel). No substantial differences in Pmel17
distribution, visualized with either antibody HMB45 (Figure
7c and d and right panels) or antibody HMB50 (not shown),
were observed in HPS-5 melanocytes relative to normal
melanocytes.
The degree to which MEL5 staining was reduced in the tips
and dendrites of HPS-5 cells was variable. Therefore, to
quantify the differences in TYRP1 distribution between HPS-5
and normal melanocytes, randomly selected fields of MEL5-
stained cells were imaged and then scored by three
independent observers in a blinded fashion. Representative
fields are shown in Figure 7a and b (left panels); several of
such fields were counted for each cell strain. Means of the
three evaluations were calculated and analyzed by Student’s
t-test. MEL5 staining (green) in the tips was found to be as
bright as or brighter than that in the cell body in 77% of the
39 normal melanocytes evaluated (Figure 7a, left panel),
compared with only 27% of 42 HPS-5 cells (Figure 7b, left
panel). This difference was found to be statistically significant
(Pp0.002).
Compartments containing melanogenic proteins were
examined further in normal and HPS-5 melanocytes. Co-
Table 1. Distribution of TYRP1 in normal and HPS-5 melanocyte organelles, using immunoEM
Particles detected by MEL5 labeling (%)1 Particles detected by aPEP1 labeling (%)2
Intracellular compartment Normal HPS-5 Normal HPS-5
Melanosomes 52 (30) 1 (3) 42 (36) 4 (8)
Small vesicles not in the Golgi region 30 (17) 26 (68) 19 (16) 22 (44)
Golgi stacks and associated vesicles 14 (8) 0 (0) 23 (19) 5 (10)
Early endosomes 21 (12) 2 (5) 15 (13) 3 (6)
Late endosomes, MVBs, lysosomes 45 (26) 5 (13) 13 (11) 11 (22)
Small tubules 12 (7) 4 (11) 6 (5) 5 (10)
Total 174 (100) 38 (100) 118 (100) 50 (100)
HPS-5, Hermansky–Pudlak syndrome 5; MVBs, multivesicular bodies.
1A total of six normal and four HPS-5 cells labeled with MEL5 were scored. Percentage of total is indicated in parenthesis.
2Five normal and six HPS-5 cells labeled with aPEP1 were scored. Percentage of total is indicated in parenthesis.
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Figure 6. TYRP1 is subject to increased lysosomal degradation in HPS-5
melanocytes. Confocal images were taken at low magnification under
identical staining and imaging conditions. Bar, 50 mm. (a) TYRP1 (MEL5)
staining in normal untreated melanocytes. (b) TYRP1 staining is slightly
increased in normal melanocytes treated with 5 mM monensin for 3 hours.
(c) Treatment of normal melanocytes with 0.5 mM MG132 for 3 hours does not
alter the intensity of TYRP1 staining. (d)TYRP1 staining is reduced in untreated
HPS-5 melanocytes, particularly in the dendrites and tips. (e) HPS-5
melanocytes treated with 5 mM monensin (an inhibitor of lysosomal function)
for 3 hours show marked increase in TYRP1 staining, predominantly in the
perinuclear area. (f) Incubation with 0.5 mM MG132 for 3 hours has minimal
effect on the intensity of TYRP1 staining in HPS-5 melanocytes. Bar¼ 50 mm.
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staining of endogenous tyrosinase (red) and MEL5 (TYRP1;
green) in normal melanocytes revealed co-localization of
these two proteins (merge; yellow) to a large extent in the
perinuclear area and in the tips (Figure 8a). In contrast, less
co-localization of tyrosinase (red) and MEL5 (green) was
observed in HPS-5 melanocytes (Figure 8b), particularly in
the tips (Figure 8b, inset). Likewise, co-localization of
tyrosinase (red) with Pmel17 (HMB45; green) was evident
in normal melanocytes, most notably in the tips (Figure 8c),
but was greatly reduced in HPS-5 melanocytes (Figure 8d).
DISCUSSION
The exact pathological mechanism responsible for the
hypopigmentation of HPS-5 melanocytes has not been
determined. HPS-5 patients are extremely unusual (Zhang
et al., 2003; Huizing et al., 2004), so the availability of
human melanocytes cultured from an HPS-5 patient pre-
sented a unique opportunity to investigate this topic. We first
showed that HPS-5 melanocytes have an approximately
normal contingent of the melanogenic protein, tyrosinase,
based upon both Western blotting (Figure 1c) and modestly
increased in vitro enzyme activity (Figure 1e). In contrast, the
assay for in vivo tyrosine hydroxylase activity, which requires
that the enzyme be properly localized to melanosomes,
showed negligible activity in HPS-5 melanocytes (Figure 1d).
In fact, DOPA histochemistry for tyrosinase demonstrated
that the enzyme was present in small vesicles but was
deficient in the proper compartment, that is, the melanosome
(Figure 3).
Studies of another melanogenic protein, TYRP1, yielded
similar results, except that the total amount of this protein was
reduced in HPS-5 melanocytes (Figure 1b). TYRP1 localized
predominantly to small vesicles throughout the cell, rather
than to melanosomes and endosomal structures (Figure 5).
Immunofluorescence further revealed a marked paucity of
TYRP1 in HPS-5 melanocytes, particularly in the dendrites
and tips (Figures 6d, 7b, and 8b). The decrement in TYRP1 is
most likely due to degradation in lysosomes as opposed to
proteasomes, as treatment with the lysosomal pH inhibitor
monensin increased TYRP1 staining (Figure 6). In contrast to
the abnormal distribution of tyrosinase and TYRP1, the early
melanosomal marker, Pmel17, appeared to localize normally
in HPS-5 melanocytes. Pmel17, which provides a matrix for
melanin production within melanosomes, decorated the
dendrites and tips of HPS-5 melanocytes in a normal fashion
(Figure 7d). The cell biological findings for HPS-5 melano-
cytes closely resemble those previously reported for HPS-3
melanocytes (Boissy et al., 2005). Specifically, HPS-3
melanocytes displayed reduced in vivo tyrosinase activity,
increased in vitro tyrosinase activity (relative to lightly
pigmented control melanocytes), abundant DOPA-positive
small vesicles throughout the cells, a reduced number of
mature stage IV melanosomes, and a normal distribution of
Pmel17 (Boissy et al., 2005). The similarity of cell biological
phenotypes for HPS-5 and HPS-3 melanocytes reflects the
interaction of the HPS5 and HPS3 proteins, along with HPS6,
in BLOC-2 (Zhang et al., 2003; Di Pietro et al., 2004; Gautam
et al., 2004).
The combined HPS-5 and HPS-3 studies suggest that in the
absence of functional BLOC-2, early-stage I/II melanosomes,
marked by Pmel17, are formed normally; however, they fail
to receive a normal contingent of melanogenic proteins to
Normal Normal
HPS-5 HPS-5
MEL5 HMB45
HMB45MEL5
a
b
c
d
Figure 7. TYRP1 is abnormally distributed in HPS-5 melanocytes. Immunofluorescence confocal microscopy shows endogenous melanosomal proteins in fixed
normal and HPS-5 melanocytes. Cells were co-stained with BODIPY 558/568 phalloidin (red; actin stain) to visualize the cell boundary, TO-PRO-3 (blue) to
stain the nucleus, and specific antibodies, as indicated (green). These images were acquired with non-uniform settings to achieve maximal signal intensity
without saturation. To quantify the differences in MEL5 (TYRP1) staining between HPS-5 and normal melanocytes, randomly selected fields of stained cells were
imaged and then scored by three independent observers in a blinded fashion. Normal melanocytes displayed increased MEL5 staining in the tips compared with
the cell body significantly more often than did HPS-5 cells. Representative low magnification fields are shown; higher magnification images are included (right
panels) to show details. (a) Normal melanocytes stained with MEL5 antibodies (recognizing TYRP1) exhibit a vesicular pattern throughout the cell with a
concentration of MEL5-positive vesicles along the dendrites and in the tips. (b) HPS-5 melanocytes demonstrate primarily perinuclear staining with MEL5.
(c) Normal melanocytes show Pmel17 (HMB45) staining in a vesicular pattern throughout the cell body, extending into the dendrites and tips. (d) HPS-5
melanocytes display the same, normal pattern of Pmel17 staining. Bar¼10 mm.
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allow maturation to later stages. TYRP1 fails to be sorted
appropriately to maturing stage II/III melanosomes, as is the
case in normal melanocytes, and is subsequently degraded in
lysosomes. Tyrosinase largely avoids such a fate possibly due
to the resistance of tyrosinase to degradation, or because
tyrosinase and TYRP1 are capable of employing distinct
pathways to reach melanosomes, as previously suggested
(Huizing et al., 2001; Raposo et al., 2001; Theos et al., 2005).
Recent studies have demonstrated the presence of BLOC-2
components on EEA1-positive tubulovesicular endosomes
and increased cycling of TYRP1 via the cell membrane in
BLOC-2-deficient cells (Di Pietro et al., 2006). Taken
together, these data support a model in which BLOC-2
functions in sorting a subset of melanosomal proteins into
transport vesicles at the early endosome. In BLOC-2-deficient
cells, these proteins are not segregated into specialized
vesicles and directed towards melanosomes. Instead they
cycle between endosomes and the cell membrane and are
ultimately degraded in lysosomes. Increased TYRP1 traffick-
ing between endosomes and the cell membrane in BLOC-2-
deficient cells may explain the observed localization of
TYRP1 to small vesicles. We cannot, however, exclude the
possibility that BLOC-2 functions in the trafficking or fusion
of these vesicles with maturing melanosomes. Further studies
will be necessary to understand exactly how BLOC-2 and
each of its components facilitate melanogenic protein
trafficking.
MATERIALS AND METHODS
Patients and cells
Normal human primary epidermal melanocytes were purchased
from Cascade Biologics (Portland, OR). HPS-5 primary epidermal
melanocytes were obtained from a forearm skin biopsy and cultured
as previously described (Naeyaert et al., 1991; Smit et al., 1998).
HPS-5 patient HPS106-5 was enrolled in a protocol approved by the
National Human Genome Research Institute Institutional Review
Board to study the clinical and molecular aspects of HPS; written
informed consent was obtained. The study was conducted according
to the Declaration of Helsinki Principles. This HPS-5 patient is
compound heterozygous for a frameshift mutation in exon 18 and a
nonsense mutation (R865X), resulting in markedly decreased HPS5
RNA on Northern blot (Huizing et al., 2004).
Western blots
Equivalent amounts of total protein, as determined by BCA assay
(Pierce Biotechnology, Rockford, IL), from two lightly pigmented
TYR
MEL5
Merge
TYR
HMB45
Merge
Normal
Normal HPS-5
HPS-5a b
c d
Figure 8. HPS-5 melanocytes demonstrate reduced co-localization of tyrosinase with either TYRP1 or Pmel17. (a) Co-staining of endogenous tyrosinase (red)
and TYRP1 (MEL5; green) in normal melanocytes revealed co-localization of these two proteins (merge; yellow) to a large extent in the perinuclear area and in
the tips (inset). (b) Less co-localization of tyrosinase (red) and TYRP1 (MEL5; green) was observed in HPS-5 melanocytes, particularly in the tips (inset). (c) Co-
localization of tyrosinase (red) with Pmel17 (HMB45; green) was evident in normal melanocytes, most notably in the tips (inset). (d) Co-localization of tyrosinase
and Pmel17 was greatly reduced in HPS-5 melanocytes. Bar: (a–d) 10 mm; insets 5 mm.
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normal melanocyte strains and HPS-5 patient melanocytes (50mg)
were loaded onto SDS-PAGE gels and immunoblotted with
polyclonal antibodies raised in rabbits against an HPS5 peptide
(TEREKFWKIGNKERDGEY; Quality Controlled Biochemicals, Hop-
kinton, MA). Proteins were detected on immunoblot using goat
polyclonal TYRP1 and mouse monoclonal tyrosinase antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA). Monoclonal a-tubulin
antibodies were used as a loading control (Calbiochem, San Diego,
CA). Blots were incubated with appropriate HRP-conjugated
secondary antibodies (1:10,000; Amersham Biosciences, Piscat-
away, NJ) and results were visualized with enhanced chemilumines-
cence (ECL Western Blotting Detection Reagents, Amersham
Biosciences, Piscataway, NJ) and exposure to CL-XPosure film
(Pierce Biotechnology).
Tyrosinase activity
Endogenous (i.e., in vitro) and functional (i.e., in vivo) tyrosinase
activity was assayed as previously described (Zhao and Boissy,
1994). For the in vitro assay, lysates from solubilized melanocytes
were incubated in 250ml of reaction mixture containing 10–25mg of
protein, 0.08 mM L-DOPA, 0.08 mM tyrosine, and 8 mCi/ml of
(3 hours) tyrosine at 371C for 1 hour. For the in vivo assay, intact
cultured melanocytes were incubated in medium containing 1mCi/
ml (3 hours) tyrosine (specific activity, 54.2 Ci/mmol) for 24 hours.
Duplicate aliquots of lysate/reaction mixture (250ml) or medium
(1 ml), respectively, were mixed with an equal volume of 10% (w/v)
activated charcoal in 0.2 N citric acid. The samples were centrifuged
at 2500 r.p.m and the supernatants were passed over a Dowex ion-
exchange column followed by a wash of 0.1 N citric acid. Radio-
activity of the eluate was counted in a liquid scintillation analyzer.
Tyrosinase activity was expressed as dpm/mg protein.
DOPA histochemistry and electron microscopy
Melanocyte cultures from a control and an HPS-5 individual,
maintained in regular MCDB-153 growth medium, were seeded into
Lab-Tek chamber slides (Nunc Inc., Naperville, IL) coated with 1%
pig gelatin and grown to 90% confluence. Melanocytes were fixed
with half-strength Karnovsky’s fixative (Karnovsky, 1965) in 0.2 M
sodium cacodylate buffer at pH 7.2 for 30 minutes at room
temperature. For DOPA histochemistry, fixed cells were incubated
in a 0.1% solution of L-DOPA twice for 2.5 hours. The cells were
washed three times in buffer and treated with 1.0% osmium
tetroxide containing 1.5% potassium ferrocyanide (Karnovsky,
1971) for 30 minutes. The cells were washed, stained en bloc with
0.5% uranyl acetate for 30 minutes, dehydrated, and embedded in
Eponate 12. Areas of the Epon cast were cut out and mounted on
Epon pegs and sectioned on an RMC MT 6,000-XL ultramicrotome.
Ultrathin sections were stained with aqueous solutions of uranyl
acetate (2%) and lead citrate (0.3%) for 15 minutes each and then
viewed and photographed in a JEOL 1,230 transmission electron
microscope. All tissue-processing supplies were purchased from Ted
Pella Inc. (Tustin, CA).
Immunoelectron microscopy
Primary human epidermal melanocytes were fixed for 2 hours at
room temperature in 2% formaldehyde with 0.2% glutaraldehyde in
0.1 M phosphate buffer. After washing in PBS, the cells were pelleted
and embedded in 12% gelatin. The pellet was divided into 1-mm3
cubes, cryoprotected in 2.3 M sucrose, and snap frozen in liquid
nitrogen. Ultra-thin cryosections were labelled with polyclonal PEP-
1 (kindly provided by Dr Vincent Hearing, NIH, MD) or MEL-5
antibody (Signet Laboratories, Dedham, MA), and secondary
labelling was performed with a rabbit anti-mouse IgG bridging
antibody (Aurion, The Netherlands) and 10 nm protein A-gold
particles (Aurion, The Netherlands). Sections were contrasted with
uranyl acetate and analyzed by a Philips electron microscope.
Fluorescence microscopy
Melanocytes were grown overnight on glass slides and fixed in 3%
paraformaldehyde. For studies of lysosome and proteasome inhibi-
tors, cells were incubated in culture media containing either 5 mM
monensin or 0.5 mM MG132 (Sigma-Aldrich, St Louis, MO) for
3 hours before fixation. The slides were blocked in PBS containing
0.1% saponin, 100mM glycine, 0.1% BSA, and 2% donkey serum
then incubated with the following mouse monoclonal antibodies
(1:200 dilution): MEL-5 (Signet Laboratories, Dedham, MA),
HMB45, and HMB50 (Lab Vision, Fremont, CA). For single antibody
stainings, cells were co-stained with BODIPY 558/568 phalloidin to
visualize the cell boundary and TO-PRO-3 to stain the nucleus
(Invitrogen, Carlsbad, CA). For double antibody stainings, rabbit
polyclonal tyrosinase was used (1:50 dilution; a kind gift of Dr
Vincent Hearing, NIH, MD). The cells were washed and incubated
with donkey anti-mouse antibodies conjugated to ALEXA-488 and/or
anti-rabbit conjugated to ALEXA-555 (Invitrogen), washed again, and
mounted in VectaShield (Vector Laboratories, Burlingame, CA).
Cells were imaged with a Zeiss 510 META confocal laser-scanning
microscope (Carl Zeiss, Microimaging Inc., Germany). All images
are one-dimensional projections of confocal z-sections, with the
exception of the dual stained tip insets in Figure 7, which are single
z-sections to assess co-localization.
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SUPPLEMENTARY MATERIAL
Figure 1. Morphological characterization of organelles and endosomal
structures present in melanocytes.
Figure 2. Quantitative analysis of TYRP1 distribution in normal and HPS-5
melanocytes.
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